Mainstay Capital Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Mainstay Capital Management’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-266	Closed	-$1K	–	426
2018 Q3	$1K	Hold	266	–	–	﹤0.01%	425
2018 Q2	$1K	Hold	266	–	–	﹤0.01%	425
2018 Q1	$0	Hold	266	–	–	﹤0.01%	447
2017 Q4	$1K	Buy	+266	New	+$817	﹤0.01%	407

Other funds holding PDLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Mainstay Capital Management's PDLI Position: Q4 2018 in Review

Mainstay Capital Management sold out of PDL BioPharma, Inc. (PDLI) in Q4 2018, closing a stake of 266 shares — an estimated $1K sold.

Mainstay Capital Management first reported a position in PDLI in Q4 2017 and held it in 4 quarters. The position peaked at $1K in Q3 2018. 154 funds tracked by Wall St. Rank hold PDLI as of Q4 2018.

Mainstay Capital Management reported no remaining PDL BioPharma, Inc. position as of Q4 2018 after selling out during the quarter.
Mainstay Capital Management sold 266 PDL BioPharma, Inc. shares in Q4 2018, an estimated $1K.
Mainstay Capital Management first reported a position in PDL BioPharma, Inc. in Q4 2017 and held it in 4 quarters.
Mainstay Capital Management's PDL BioPharma, Inc. position peaked at $1K in Q3 2018.
154 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2018.

Based on Mainstay Capital Management's 13F filing for Q4 2018, filed 8 Feb 2019.